[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626392":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":22,"locations":22,"responsibleParty":23,"collaborators":22,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":30,"acronym":22,"eligibilityCriteria":31,"healthyVolunteers":27,"sex":32,"minAge":33,"maxAge":22,"enrollmentInfo":34,"targetDuration":22,"studyType":37,"phases":38,"briefSummary":41,"conditions":42,"keywords":22,"overallStatus":47,"whyStopped":22,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":22},{"fullName":5,"class":6},"Betta Pharmaceuticals Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study BPI-572270 in adults with specific RAS mutant advanced solid tumors","EXPERIMENTAL","Capsules; Administer once a day on an empty stomach.",[13],"Drug: BPI-572270",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","BPI-572270","Oral Tablets",[9],[21],"BPI-572270 Capsule",null,{"type":24,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100626392","phase-1-study-of-bpi-572270-in-patients-with-advanced-solid-tumors-harboring-specific-mutations-in-ras-100626392",false,"NCT07435038","Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","A Phase I\u002FII Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS.","Inclusion Criteria:\n\n* Histologically confirmed advanced solid tumor with RAS mutations identified through deoxyribonucleic acid (DNA) sequencing.\n* Have received prior standard therapy appropriate for tumor type and stage.\n* Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Adequate organ function.\n\nExclusion Criteria:\n\n* Primary central nervous system (CNS) tumors active and untreated brain metastases.\n* Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication.\n* History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and\u002For impact their ability to comply with the protocol prior\u002Fconcomitant therapy","ALL","18 Years",{"count":35,"type":36},120,"ESTIMATED","INTERVENTIONAL",[39,40],"PHASE1","PHASE2","Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.",[43,44,45,46],"Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Advanced Solid Tumors","NOT_YET_RECRUITING","2026-03-08",{"date":50,"type":51},"2026-03-11","ACTUAL",{"date":53,"type":36},"2026-02-12",{"date":55,"type":36},"2029-10-28",{"name":5,"class":6}]